Trial Profile
An Open-label Extension (OLE), Expanded Access Study, to Assess Long-term Safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) With Methylprednisolone (4mg Bid) in Patients Who Completed Study Number CHL-AA-201
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Methylprednisolone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Expanded access
- 20 Jul 2020 Status changed to completed.
- 21 Sep 2016 New trial record